Nanomedicine embraces the treatment and prevention of acute kidney injury to chronic kidney disease transition: evidence, challenges, and opportunities

Abstract

Acute kidney injury (AKI), a common kidney disease in which renal function decreases rapidly due to various etiologic factors, is an important risk factor for chronic kidney disease (CKD). The pathogenesis of AKI leading to CKD is complex, and effective treatments are still lacking, which seriously affects the prognosis and quality of life of patients with kidney disease. Nanomedicine, a discipline at the intersection of medicine and nanotechnology, has emerged as a promising avenue for treating kidney diseases ranging from AKI to CKD. Increasing evidence has validated the therapeutic potential of nanomedicine in AKI; however, little attention has been paid to its effect on AKI for patients with CKD. In this review, we systematically emphasize the major pathophysiology of the AKI-to-CKD transition and summarize the treatment effects of nanomedicine on this transition. Furthermore, we discuss the key role of nanomedicine in the regulation of targeted drug delivery, inflammation, oxidative stress, ferroptosis, and apoptosis during the transition from AKI to CKD. Additionally, this review demonstrates that the integration of nanomedicine into nephrology offers unprecedented precision and efficacy in the management of conditions ranging from AKI to CKD, including the design and preparation of multifunctional nanocarriers to overcome biological barriers and deliver therapeutics specifically to renal cells. In summary, nanomedicine holds significant potential for revolutionizing the management of AKI-to-CKD transition, thereby providing a promising opportunity for the future treatment of kidney diseases.

Keywords

Nanomedicine / Acute kidney injury / Chronic kidney disease / Treatment

References

[1] Kurzhagen JT, Dellepiane S, Cantaluppi V, Rabb H AKI: an increasingly recognized risk factor for CKD development and progression. J Nephrol 2020; 33: 1171-87. https://doi.org/10.1007/s40620-020-00793-2.

[2] Xiang Y, Fu Y, Wu W, Tang C, Dong Z Autophagy in acute kidney injury and maladaptive kidney repair. Burns. Trauma 2023; 11: tkac059. https://doi.org/10.1093/burnst/tkac059.

[3] Mack M, Yanagita M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int 2015; 87: 297-307. https://doi.org/10.1038/ki.2014.287.

[4] Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int 2019; 96: 1083-99. https://doi.org/10.1016/j.kint.2019.05.026.

[5] He L, Wei Q, Liu J, Yi M, Liu Y, Liu H. et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int 2017; 92: 1071-83. https://doi.org/10.1016/j.kint.2017.06.030.

[6] Wang B, Xu J, Fu P, Ma L. MicroRNAs in septic acute kidney injury. Burns & Trauma 2023; 11: tkad008. https://doi.org/10.1093/burnst/tkad008.

[7] Adhikari A, Mondal S, Chatterjee T, das M, Biswas P, Ghosh R. et al. Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice. Commun Biol 2021; 4: 1013. https://doi.org/10.1038/s42003-021-02546-8.

[8] Lee T-Y, Lu H-H, Cheng H-T, Huang HC, Tsai YJ, Chang IH. et al. Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis. J Control Release 2023; 354: 417-28. https://doi.org/10.1016/j.jconrel.2022.12.059.

[9] Du B, Yu M, Zheng J. Transport and interactions of nanoparticles in the kidneys. Nature Reviews Materials 2018; 3: 358-74. https://doi.org/10.1038/s41578-018-0038-3.

[10] Geo HN, Murugan DD, Chik Z, Norazit A, Foo YY, Leo BF. et al. Renal Nano-drug delivery for acute kidney injury: current status and future perspectives. J Control Release 2022; 343: 237-54. https://doi.org/10.1016/j.jconrel.2022.01.033.

[11] Alidori S, Akhavein N, Thorek DLJ, Behling K, Romin Y, Queen D. et al. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med 2016; 8: 331ra39. https://doi.org/10.1126/scitranslmed.aac9647.

[12] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021; 20: 101-24. https://doi.org/10.1038/s41573-020-0090-8.

[13] Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 2013; 65: 21-3. https://doi.org/10.1016/j.addr.2012.04.010.

[14] Cho K, Wang X, Nie S, Chen Z(G, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310-6. https://doi.org/10.1158/1078-0432.CCR-07-1441.

[15] Ying Y, Tang Q, Han D, Mou S. Nucleic acid nanotechnology for diagnostics and therapeutics in acute kidney injury. Int J Mol Sci 2022; 23. https://doi.org/10.3390/ijms23063093.

[16] Watchorn J, Huang D, Bramham K, Hutchings S Decreased renal cortical perfusion, independent of changes in renal blood flow and sublingual microcirculatory impairment, is associated with the severity of acute kidney injury in patients with septic shock. Crit Care 2022; 26: 261. https://doi.org/10.1186/s13054-022-04134-6.

[17] Dennis JM, Witting PK. Protective role for antioxidants in acute kidney disease. Nutrients 2017; 9. https://doi.org/10.3390/nu9070718.

[18] Honda T, Hirakawa Y, Nangaku M. The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract 2019; 38: 414-26. https://doi.org/10.23876/j.krcp.19.063.

[19] Li Z, Guo H, Li J, Ma T, Zhou S, Zhang Z. et al. Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function. Clin Sci (Lond) 2020; 134: 2469-87. https://doi.org/10.1042/CS20191088.

[20] Hall AM, Rhodes GJ, Sandoval RM, Corridon PR, Molitoris BA In vivo multiphoton imaging of mitochondrial structure and function during acute kidney injury. Kidney Int 2013; 83: 72-83. https://doi.org/10.1038/ki.2012.328.

[21] Tanaka S, Tanaka T, Kawakami T, Takano H, Sugahara M, Saito H. et al. Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury. Kidney Int 2017; 92: 154-64. https://doi.org/10.1016/j.kint.2017.01.014.

[22] Tammaro A, Scantlebery AML, Rampanelli E, Borrelli C, Claessen N, Butter LM. et al. TREM1/3 deficiency impairs tissue repair after acute kidney injury and mitochondrial metabolic flexibility in tubular epithelial cells. Front Immunol 2019; 10: 1469. https://doi.org/10.3389/fimmu.2019.01469.

[23] Mapuskar KA, Wen H, Holanda DG, Rastogi P, Steinbach E, Han R. et al. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biol 2019; 20: 98-106. https://doi.org/10.1016/j.redox.2018.09.020.

[24] Wang J, Zhu P, Li R, Ren J, Zhou H Fundc1-dependent mitophagy is obligatory to ischemic preconditioning-conferred renoprotection in ischemic AKI via suppression of Drp1-mediated mitochondrial fission. Redox Biol 2020; 30: 101415. https://doi.org/10.1016/j.redox.2019.101415.

[25] Perry HM, Huang L, Wilson RJ, Bajwa A, Sesaki H, Yan Z. et al. Dynamin-related protein 1 deficiency promotes recovery from AKI. J Am Soc Nephrol 2018; 29: 194-206. https://doi.org/10.1681/ASN.2017060659.

[26] Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008; 327: 300-7. https://doi.org/10.1124/jpet.108.139162.

[27] Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 2010; 21: 31-41. https://doi.org/10.1681/ASN.2008111133.

[28] Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-43. https://doi.org/10.1038/nm.2144.

[29] Ying Y, Kim J, Westphal SN, Long KE, Padanilam BJ Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. J Am Soc Nephrol 2014; 25: 2707-16. https://doi.org/10.1681/ASN.2013121270.

[30] Sutton TA, Hato T, Mai E, Yoshimoto M, Kuehl S, Anderson M. et al. p53 is renoprotective after ischemic kidney injury by reducing inflammation. J Am Soc Nephrol 2013; 24: 113-24. https://doi.org/10.1681/ASN.2012050469.

[31] Yan H-F, Zou T, Tuo Q-Z, Xu S, Li H, Belaidi AA. et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther 2021; 6: 49. https://doi.org/10.1038/s41392-020-00428-9.

[32] Ni L, Yuan C, Wu X. Targeting ferroptosis in acute kidney injury. Cell Death Dis 2022; 13: 182. https://doi.org/10.1038/s41419-022-04628-9.

[33] Ide S, Kobayashi Y, Ide K, Strausser SA, Abe K, Herbek S. et al. Ferroptotic stress promotes the accumulation of pro-inflammatory proximal tubular cells in maladaptive renal repair. elife 2021; 10: 10. https://doi.org/10.7554/eLife.68603.

[34] Zhang B, Chen X, Ru F, Gan Y, Li B, Xia W. et al. Liproxstatin-1 attenuates unilateral ureteral obstruction-induced renal fibrosis by inhibiting renal tubular epithelial cells ferroptosis. Cell Death Dis 2021; 12: 843. https://doi.org/10.1038/s41419-021-04137-1.

[35] Guo R, Duan J, Pan S, Cheng F, Qiao Y, Feng Q. et al. The road from AKI to CKD: molecular mechanisms and therapeutic targets of Ferroptosis. Cell Death Dis 2023; 14: 426. https://doi.org/10.1038/s41419-023-05969-9.

[36] Gao J, Zhou Q, Wu D, Chen L Mitochondrial iron metabolism and its role in diseases. Clin Chim Acta 2021; 513: 6-12. https://doi.org/10.1016/j.cca.2020.12.005.

[37] Li Z, Lu S, Li X. The role of metabolic reprogramming in tubular epithelial cells during the progression of acute kidney injury. Cell Mol Life Sci 2021; 78: 5731-41. https://doi.org/10.1007/s00018-021-03892-w.

[38] Zhu Z, Hu J, Chen Z, Feng J, Yang X, Liang W. et al. Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming. Metabolism 2022; 131: 155194. https://doi.org/10.1016/j.metabol.2022.155194.

[39] Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov 2022; 21: 379-99. https://doi.org/10.1038/s41573-022-00410-w.

[40] Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol 2023; 23: 236-50. https://doi.org/10.1038/s41577-022-00763-8.

[41] Lv L-L, Feng Y, Wu M, Wang B, Li ZL, Zhong X. et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death Differ 2020; 27: 210-26. https://doi.org/10.1038/s41418-019-0349-y.

[42] Mossberg M, Ståhl A-L, Kahn R, Kristoffersson AC, Tati R, Heijl C. et al. C1-inhibitor decreases the release of Vasculitis-like chemotactic endothelial microvesicles. J Am Soc Nephrol 2017; 28: 2472-81. https://doi.org/10.1681/ASN.2016060637.

[43] Guan H, Peng R, Mao L, Fang F, Xu B, Chen M. Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes. Exp Cell Res 2020; 392: 112007. https://doi.org/10.1016/j.yexcr.2020.112007.

[44] Zhao S, Li W, Yu W, Rao T, Li H, Ruan Y. et al. Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys. Theranostics 2021; 11: 8660-73. https://doi.org/10.7150/thno.62820.

[45] Murakami T, Oakes M, Ogura M, Tovar V, Yamamoto C, Mitsuhashi M Development of glomerulus-, tubule-, and collecting duct-specific mRNA assay in human urinary exosomes and microvesicles. PLoS One 2014; 9: e109074. https://doi.org/10.1371/journal.pone.0109074.

[46] Zhou H, Cheruvanky A, Hu X, Matsumoto T, Hiramatsu N, Cho ME. et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int 2008; 74: 613-21. https://doi.org/10.1038/ki.2008.206.

[47] Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci USA 2021; 118. https://doi.org/10.1073/pnas.2109256118.

[48] Dadfar SM, Roemhild K, Drude NI, von Stillfried S, Knüchel R, Kiessling F. et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev 2019; 138: 302-25. https://doi.org/10.1016/j.addr.2019.01.005.

[49] Lisik K, Krokosz A. Application of carbon nanoparticles in oncology and regenerative medicine. Int J Mol Sci 2021; 22. https://doi.org/10.3390/ijms22158341.

[50] Tiwari JN, Tiwari RN, Kim KS. Zero-dimensional, one-dimensional, two-dimensional and three-dimensional nanostructured materials for advanced electrochemical energy devices. Prog Mater Sci 2012; 57: 724-803. https://doi.org/10.1016/j.pmatsci.2011.08.003.

[51] Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology 2022; 20: 395. https://doi.org/10.1186/s12951-022-01605-4.

[52] Park E-Y, Oh D, Park S, Kim W, Kim C New contrast agents for photoacoustic imaging and theranostics: recent 5-year overview on phthalocyanine/naphthalocyanine-based nanoparticles. APL Bioeng 2021; 5: 031510. https://doi.org/10.1063/5.0047660.

[53] Yetisen AK, Montelongo Y, da Cruz VF, Martinez-Hurtado JL, Neupane S, Butt H. et al. Reusable, robust, and accurate laser-generated photonic nanosensor. Nano Lett 2014; 14: 3587-93. https://doi.org/10.1021/nl5012504.

[54] Łukasiewicz S, Szczepanowicz K, Podgórna K, Błasiak E, Majeed N, Ogren SOÖ. et al. Encapsulation of clozapine in polymeric nanocapsules and its biological effects. Colloids Surf B Biointerfaces 2016; 140: 342-52. https://doi.org/10.1016/j.colsurfb.2015.12.044.

[55] Szcze˛ch M, Szczepanowicz K. Polymeric Core-Shell nanoparticles prepared by spontaneous emulsification solvent evaporation and functionalized by the layer-by-layer method. Nanomaterials (Basel) 2020; 10: 10. https://doi.org/10.3390/nano10030496.

[56] Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zakharova LY. et al. Nanoparticle delivery Systems in the Treatment of diabetes complications. Molecules 2019; 24. https://doi.org/10.3390/molecules24234209.

[57] Yan X, Bernard J, Ganachaud F. Nanoprecipitation as a simple and straightforward process to create complex polymeric colloidal morphologies. Adv Colloid Interf Sci 2021; 294: 102474. https://doi.org/10.1016/j.cis.2021.102474.

[58] Oroojalian F, Charbgoo F, Hashemi M, Amani A, Yazdian-Robati R, Mokhtarzadeh A. et al. Recent advances in nanotechnology-based drug delivery systems for the kidney. J Control Release 2020; 321: 442-62. https://doi.org/10.1016/j.jconrel.2020.02.027.

[59] da Silva Júnior WF, de Oliveira Pinheiro JG, Moreira CDLFA, de Souza FJJ, de Lima ÁAN. Chapter 15-Alternative Technologies to Improve Solubility and Stability of Poorly Water-Soluble Drugs. In: Grumezescu AM, editor. Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics: Elsevier; 2017. p. 281-305, https://doi.org/10.1016/B978-0-323-52725-5.00015-0.

[60] Deng S, Gigliobianco MR, Censi R, di Martino P Polymeric Nanocapsules as Nanotechnological alternative for drug delivery system: current status, challenges and opportunities. Nanomaterials (Basel) 2020; 10: 10. https://doi.org/10.3390/nano10050847.

[61] Yu H, Lin T, Chen W, Cao W, Zhang C, Wang T. et al. Size and temporal-dependent efficacy of oltipraz-loaded PLGA nanoparticles for treatment of acute kidney injury and fibrosis. Biomaterials 2019; 219: 119368. https://doi.org/10.1016/j.biomaterials.2019.119368.

[62] Huang H, Feng W, Chen Y, Shi J. Inorganic nanoparticles in clinical trials and translations. Nano Today 2020; 35: 100972. https://doi.org/10.1016/j.nantod.2020.100972.

[63] Fan J, Cheng Y, Sun M. Functionalized gold nanoparticles: synthesis, properties and biomedical applications. Chem Rec 2020; 20: 1474-504. https://doi.org/10.1002/tcr.202000087.

[64] Kim H-M, Hong Jeong D, Lee H-Y, Park JH, Lee SK Improved stability of gold nanoparticles on the optical fiber and their application to refractive index sensor based on localized surface plasmon resonance. Opt Laser Technol 2019; 114: 171-8. https://doi.org/10.1016/j.optlastec.2019.02.002.

[65] Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM. et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009; 75: 465-74. https://doi.org/10.1038/ki.2008.496.

[66] Iversen NK, Frische S, Thomsen K, Laustsen C, Pedersen M, Hansen PBL. et al. Superparamagnetic iron oxide polyacrylic acid coated γ-Fe₂O₃ nanoparticles do not affect kidney function but cause acute effect on the cardiovascular function in healthy mice. Toxicol Appl Pharmacol 2013; 266: 276-88. https://doi.org/10.1016/j.taap.2012.10.014.

[67] Schutter R, Lantinga VA, Borra RJH, Moers C MRI for diagnosis of post-renal transplant complications: current state-of-the-art and future perspectives. MAGMA 2020; 33: 49-61. https://doi.org/10.1007/s10334-019-00813-8.

[68] Richbourg, Peppas NA. The swollen polymer network hypothesis: quantitative models of hydrogel swelling, stiffness, and solute transport. 2020; 105: 101243. https://doi.org/10.1016/j.progpolymsci.2020.101243.

[69] Cao H, Duan L, Zhang Y, Cao J, Zhang K. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct Target Ther 2021; 6: 426. https://doi.org/10.1038/s41392-021-00830-x.

[70] Jansen K, Schuurmans CL, Jansen J, Masereeuw R, Vermonden T Hydrogel-based cell therapies for kidney regeneration: current trends in biofabrication and in vivo repair. Curr Pharm Des 2017; 23: 3845-57. https://doi.org/10.2174/1381612823666170710155726.

[71] Shaikh H, Rho JY, Macdougall LJ, Gurnani P, Lunn AM, Yang J. et al. Hydrogel and Organogel formation by hierarchical self-assembly of cyclic peptides nanotubes. Chemistry 2018; 24: 19066-74. https://doi.org/10.1002/chem.201804576.

[72] Ahmed EM. Hydrogel: preparation, characterization, and applications: a review. J Adv Res 2015; 6: 105-21. https://doi.org/10.1016/j.jare.2013.07.006.

[73] Feng G, Zhang J, Li Y, Nie Y, Zhu D, Wang R. et al. IGF-1 C domain-modified hydrogel enhances cell therapy for AKI. J Am Soc Nephrol 2016; 27: 2357-69. https://doi.org/10.1681/ASN.2015050578.

[74] Liu Y, Cui J, Wang H, Hezam K, Zhao X, Huang H. et al. Enhanced therapeutic effects of MSC-derived extracellular vesicles with an injectable collagen matrix for experimental acute kidney injury treatment. Stem Cell Res Ther 2020; 11: 161. https://doi.org/10.1186/s13287-020-01668-w.

[75] Pinheiro AV, Han D, Shih WM, Yan H Challenges and opportunities for structural DNA nanotechnology. Nat Nanotechnol 2011; 6: 763-72. https://doi.org/10.1038/nnano.2011.187.

[76] Udomprasert A, Kangsamaksin T. DNA origami applications in cancer therapy. Cancer Sci 2017; 108: 1535-43. https://doi.org/10.1111/cas.13290.

[77] Wang P, Rahman MA, Zhao Z, Weiss K, Zhang C, Chen Z. et al. Visualization of the cellular uptake and trafficking of DNA origami nanostructures in cancer cells. J Am Chem Soc 2018; 140: 2478-84. https://doi.org/10.1021/jacs.7b09024.

[78] Mathur D, Galvan AR, Green CM, Liu K, Medintz IL Uptake and stability of DNA nanostructures in cells: a cross-sectional overview of the current state of the art. Nanoscale 2023; 15: 2516-28. https://doi.org/10.1039/D2NR05868E.

[79] Dai L, Liu P, Hu X, Zhao X, Shao G, Tian Y DNA origami: an outstanding platform for functions in nanophotonics and cancer therapy. Analyst 2021; 146: 1807-19. https://doi.org/10.1039/D0AN02160A.

[80] Lawrence MG, Altenburg MK, Sanford R, Willett JD, Bleasdale B, Ballou B. et al. Permeation of macromolecules into the renal glomerular basement membrane and capture by the tubules. Proc Natl Acad Sci USA 2017; 114: 2958-63. https://doi.org/10.1073/pnas.1616457114.

[81] Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA. et al. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci USA 2010; 107: 12369-74. https://doi.org/10.1073/pnas.0913667107.

[82] Liu Q, Chen X, Kan M, Yang J, Gong Q, Jin R. et al. Gypenoside XLIX loaded nanoparticles targeting therapy for renal fibrosis and its mechanism. Eur J Pharmacol 2021; 910: 174501. https://doi.org/10.1016/j.ejphar.2021.174501.

[83] Vallorz EL, Blohm-Mangone K, Schnellmann RG, Mansour HM Formoterol PLGA-PEG nanoparticles induce mitochondrial biogenesis in renal proximal tubules. AAPS J 2021; 23: 88. https://doi.org/10.1208/s12248-021-00619-4.

[84] Samadarsi R, Dutta D. Anti-oxidative effect of mangiferin-chitosan nanoparticles on oxidative stress-induced renal cells. Int J Biol Macromol 2020; 151: 36-46. https://doi.org/10.1016/j.ijbiomac.2020.02.112.

[85] Liu D, Shu G, Jin F, Qi J, Xu X, Du Y. et al. ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule. Sci Adv 2020; 6: 6. https://doi.org/10.1126/sciadv.abb7422.

[86] Hu J-B, Li S-J, Kang X-Q, Qi J, Wu J-H, Wang X-J. et al. CD44-targeted hyaluronic acid-curcumin prodrug protects renal tubular epithelial cell survival from oxidative stress damage. Carbohydr Polym 2018; 193: 268-80. https://doi.org/10.1016/j.carbpol.2018.04.011.

[87] Guo H, Lan T, Lu X, Geng K, Shen X, Mao H. et al. ROS-responsive curcumin-encapsulated nanoparticles for AKI therapy via promoting lipid degradation in renal tubules. J Mater Chem B 2024; 12: 3063-78. https://doi.org/10.1039/D3TB02318D.

[88] Wang H, Yu D, Fang J, Zhou Y, Li D, Liu Z. et al. Phenol-like group functionalized graphene quantum dots structurally mimicking natural antioxidants for highly efficient acute kidney injury treatment. Chem Sci 2020; 11: 12721-30. https://doi.org/10.1039/D0SC03246H.

[89] Gao J, Liu Y, Jiang B, Cao W, Kan Y, Chen W. et al. Phenylenediamine-based carbon Nanodots alleviate acute kidney injury via preferential renal accumulation and antioxidant capacity. ACS Appl Mater Interfaces 2020; 12: 31745-56. https://doi.org/10.1021/acsami.0c05041.

[90] Rosenkrans ZT, Sun T, Jiang D, Chen W, Barnhart TE, Zhang Z. et al. Selenium-doped carbon quantum dots act as broad-Spectrum antioxidants for acute kidney injury management. Adv Sci (Weinh) 2020; 7: 2000420. https://doi.org/10.1002/advs.202000420.

[91] Ni D, Jiang D, Kutyreff CJ, Lai J, Yan Y, Barnhart TE. et al. Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 2018; 9: 5421. https://doi.org/10.1038/s41467-018-07890-8.

[92] Hou J, Wang H, Ge Z, Zuo T, Chen Q, Liu X. et al. Treating acute kidney injury with Antioxidative black phosphorus Nanosheets. Nano Lett 2020; 20: 1447-54. https://doi.org/10.1021/acs.nanolett.9b05218.

[93] Yu H, Jin F, Liu D, Shu G, Wang X, Qi J. et al. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. Theranostics 2020; 10: 2342-57. https://doi.org/10.7150/thno.40395.

[94] Jiang D, Ge Z, Im H-J, England CG, Ni D, Hou J. et al. DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2018; 2: 865-77. https://doi.org/10.1038/s41551-018-0317-8.

[95] Chen Q, Ding F, Zhang S, Li Q, Liu X, Song H. et al. Sequential therapy of acute kidney injury with a DNA Nanodevice. Nano Lett 2021; 21: 4394-402. https://doi.org/10.1021/acs.nanolett.1c01044.

[96] Yan R, Cui W, Ma W, Li J, Liu Z, Lin Y. Typhaneoside-tetrahedral framework nucleic acids system: mitochondrial recovery and Antioxidation for acute kidney injury treatment. ACS Nano 2023; 17: 8767-81. https://doi.org/10.1021/acsnano.3c02102.

[97] Zhang Q, Lin S, Wang L, Peng S, Tian T, Li S. et al. Tetrahedral framework nucleic acids act as antioxidants in acute kidney injury treatment. Chem Eng J 2021; 413: 127426. https://doi.org/10.1016/j.cej.2020.127426.

[98] Tsurkan MV, Hauser PV, Zieris A, Carvalhosa R, Bussolati B, Freudenberg U. et al. Growth factor delivery from hydrogel particle aggregates to promote tubular regeneration after acute kidney injury. J Control Release 2013; 167: 248-55. https://doi.org/10.1016/j.jconrel.2013.01.030.

[99] Zhao M, Zhou Y, Liu S, Li L, Chen Y, Cheng J. et al. Control release of mitochondria-targeted antioxidant by injectable self-assembling peptide hydrogel ameliorated persistent mitochondrial dysfunction and inflammation after acute kidney injury. Drug Deliv 2018; 25: 546-54. https://doi.org/10.1080/10717544.2018.1440445.

[100] van Alem CMA, Boonstra M, Prins J, Bezhaeva T, van Essen MF, Ruben JM. et al. Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat. Nephrol Dial Transplant 2018; 33: 44-53. https://doi.org/10.1093/ndt/gfx204.

[101] Zhang J, Gu L, Jiang Y, Ma Y, Zhang Z, Shen S. et al. Artesunate-Nanoliposome-TPP, a novel drug delivery system that targets the mitochondria, attenuates cisplatin-induced acute kidney injury by suppressing oxidative stress and inflammatory effects. Int J Nanomedicine 2024; 19: 1385-408. https://doi.org/10.2147/IJN.S444076.

[102] Huang Z-W, Shi Y, Zhai Y-Y, Du C-C, Zhai J, Yu R-J. et al. Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury. J Control Release 2021; 334: 275-89. https://doi.org/10.1016/j.jconrel.2021.04.033.

[103] Sun J, Zhao X, Shen H, Dong J, Rong S, Cai W, et al. CD44-targeted melanin-based nanoplatform for alleviation of ischemia/reperfusion-induced acute kidney injury. J Control Release 2024; 368: 1-14. https://doi.org/10.1016/j.jconrel.2024.02.021.

[104] Rahdar A, Hasanein P, Bilal M, Beyzaei H, Kyzas GZ. et al. Quercetin-loaded F127 nanomicelles: antioxidant activity and protection against renal injury induced by gentamicin in rats. Life Sci 2021; 276: 119420. https://doi.org/10.1016/j.lfs.2021.119420.

[105] Zhao M, Guo J, Tian C, Yan M, Zhou Y, Liu C. et al. Dual-targeted nanoparticles with removing ROS inside and outside mitochondria for acute kidney injury treatment. Nanomedicine 2024; 55: 102725. https://doi.org/10.1016/j.nano.2023.102725.

[106] Zhang D-Y, Tu T, Younis MR, Zhu KS, Liu H, Lei S. et al. Clinically translatable gold nanozymes with broad spectrum antioxidant and anti-inflammatory activity for alleviating acute kidney injury. Theranostics 2021; 11: 9904-17. https://doi.org/10.7150/thno.66518.

[107] Zhang D-Y, Liu H, Younis MR, Lei S, Yang C, Lin J. et al. Ultrasmall platinum nanozymes as broad-spectrum antioxidants for theranostic application in acute kidney injury. Chem Eng J 2021; 409: 127371. https://doi.org/10.1016/j.cej.2020.127371.

[108] Matsushita K, Toyoda T, Yamada T, Morikawa T, Ogawa K Specific expression of survivin, SOX9, and CD44 in renal tubules in adaptive and maladaptive repair processes after acute kidney injury in rats. J Appl Toxicol 2021; 41: 607-17. https://doi.org/10.1002/jat.4069.

[109] Kim CK, Kim T, Choi I-Y, Soh M, Kim D, Kim YJ. et al. Ceria nanoparticles that can protect against ischemic stroke. Angew Chem Int Ed Engl 2012; 51: 11039-43. https://doi.org/10.1002/anie.201203780.

[110] AlBasher G, Alfarraj S, Alarifi S, Alkhtani S, Almeer R, Alsultan N. et al. Nephroprotective role of selenium nanoparticles against glycerol-induced acute kidney injury in rats. Biol Trace Elem Res 2020; 194: 444-54. https://doi.org/10.1007/s12011-019-01793-5.

[111] Liu M, Huang Q, Zhu Y, Chen L, Li Y, Gong Z. et al. Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury. Materials Today Bio 2022; 13: 100215. https://doi.org/10.1016/j.mtbio.2022.100215.

[112] Wang K, Zhang Y, Mao W, Feng W, Lu S, Wan J. et al. Engineering Ultrasmall Ferroptosis-targeting and reactive oxygen/nitrogen species-scavenging Nanozyme for alleviating acute kidney injury. Adv Funct Mater 2022; 32: 2109221. https://doi.org/10.1002/adfm.202109221.

[113] Xie X, Zhang Y, Su X, Wang J, Yao X, Lv D. et al. Targeting iron metabolism using gallium nanoparticles to suppress ferroptosis and effectively mitigate acute kidney injury. Nano Res 2022; 15: 6315-27. https://doi.org/10.1007/s12274-022-4257-y.

[114] Deng L, Xiao M, Wu A, He D, Huang S, Deng T. et al. Se/albumin nanoparticles for inhibition of Ferroptosis in tubular epithelial cells during acute kidney injury. 2022; 5: 227-36. https://doi.org/10.1021/acsanm.1c02706.

[115] Zhang Y, Wu J, An Q, Zhu H, Su X, Wang Y. et al. Renal tubule-targeted dexrazoxane suppresses ferroptosis in acute kidney injury by inhibiting ACMSD. Nano Res 2023; 16: 9701-14. https://doi.org/10.1007/s12274-023-5547-8.

[116] Li J, Wei L, Zhang Y, Wu M Tetrahedral DNA nanostructures inhibit Ferroptosis and apoptosis in cisplatin-induced renal injury. ACS Appl Bio Mater 2021; 4: 5026-32. https://doi.org/10.1021/acsabm.1c00294.

[117] Zhang K, Li R, Chen X, Yan H, Li H, Zhao X. et al. Renal endothelial cell-targeted extracellular vesicles protect the kidney from ischemic injury. Adv Sci (Weinh) 2023; 10: e2204626. https://doi.org/10.1002/advs.202204626.

[118] Yea J-H, Yoon YM, Lee JH, Yun CW, Lee SH Exosomes isolated from melatonin-stimulated mesenchymal stem cells improve kidney function by regulating inflammation and fibrosis in a chronic kidney disease mouse model. J Tissue Eng 2021; 12: 20417314211059624.

[119] Tang T-T, Wang B, Wu M, Li ZL, Feng Y, Cao JY. et al. Extracellular vesicle-encapsulated IL-10 as novel nanotherapeutics against ischemic AKI. Sci Adv 2020; 6: eaaz0748. https://doi.org/10.1126/sciadv.aaz0748.

[120] Tang T-T, Wang B, Li Z-L, Wen Y, Feng ST, Wu M. et al. Kim-1 targeted extracellular vesicles: a new therapeutic platform for RNAi to treat AKI. J Am Soc Nephrol 2021; 32: 2467-83. https://doi.org/10.1681/ASN.2020111561.

[121] Zhang C, Shang Y, Chen X, Midgley AC, Wang Z, Zhu D. et al. Supramolecular nanofibers containing arginine-glycine-aspartate (RGD) peptides boost therapeutic efficacy of extracellular vesicles in kidney repair. ACS Nano 2020; 14: 12133-47. https://doi.org/10.1021/acsnano.0c05681.

[122] Zhou Y, Liu S, Zhao M, Wang C, Li L, Yuan Y. et al. Injectable extracellular vesicle-released self-assembling peptide nanofiber hydrogel as an enhanced cell-free therapy for tissue regeneration. J Control Release 2019; 316: 93-104. https://doi.org/10.1016/j.jconrel.2019.11.003.

[123] Tang W, Panja S, Jogdeo CM, Tang S, Ding L, Yu A. et al. Modified chitosan for effective renal delivery of siRNA to treat acute kidney injury. Biomaterials 2022; 285: 121562. https://doi.org/10.1016/j.biomaterials.2022.121562.

[124] Tang W, Chen Y, Jang H-S, Hang Y, Jogdeo CM, Li J. et al. Preferential siRNA delivery to injured kidneys for combination treatment of acute kidney injury. J Control Release 2022; 341: 300-13. https://doi.org/10.1016/j.jconrel.2021.11.029.

[125] Cao J-Y, Wang B, Tang T-T, Wen Y, Li ZL, Feng ST. et al. Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. Theranostics 2021; 11: 5248-66. https://doi.org/10.7150/thno.54550.

[126] Thai HBD, Kim K-R, Hong KT, Voitsitskyi T, Lee JS, Mao C. et al. Kidney-targeted cytosolic delivery of siRNA using a small-sized mirror DNA tetrahedron for enhanced potency. ACS Cent Sci 2020; 6: 2250-8. https://doi.org/10.1021/acscentsci.0c00763.

[127] Li R, Li Y, Zhang J, Liu Q, Wu T, Zhou J. et al. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. J Control Release 2020; 320: 32-44. https://doi.org/10.1016/j.jconrel.2020.01.017.

[128] Aslam Saifi M, Hirawat R, Godugu C. Lactoferrin-decorated cerium oxide nanoparticles prevent renal injury and fibrosis. Biol Trace Elem Res 2023; 201: 1837-45. https://doi.org/10.1007/s12011-022-03284-6.

[129] Midgley AC, Wei Y, Zhu D, Gao F, Yan H, Khalique A. et al. Multifunctional natural polymer nanoparticles as Antifibrotic gene carriers for CKD therapy. J Am Soc Nephrol 2020; 31: 2292-311. https://doi.org/10.1681/ASN.2019111160.

[130] Karlstetter M, Kopatz J, Aslanidis A, Shahraz A, Caramoy A, Linnartz-Gerlach B. et al. Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina. EMBO Mol Med 2017; 9: 154-66. https://doi.org/10.15252/emmm.201606627.

[131] Quesenberry PJ, Goldberg LR, Aliotta JM, Dooner MS, Pereira MG, Wen S. et al. Cellular phenotype and extracellular vesicles: basic and clinical considerations. Stem Cells Dev 2014; 23: 1429-36. https://doi.org/10.1089/scd.2013.0594.

[132] Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm 2012; 81: 463-9. https://doi.org/10.1016/j.ejpb.2012.04.007.

[133] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical Practice 2012; 120: c179-84. https://doi.org/10.1159/000339789.

[134] Stamopoulos D, Bouziotis P, Benaki D, Kotsovassilis C, Zirogiannis PN Utilization of nanobiotechnology in haemodialysis: mock-dialysis experiments on homocysteine. Nephrology Dialysis Transplantation 2008; 23: 3234-9. https://doi.org/10.1093/ndt/gfn189.

[135] Ba X, Ye T, Shang H, Tong Y, Huang Q, He Y. et al. Recent advances in nanomaterials for the treatment of acute kidney injury. ACS Appl Mater Interfaces 2024; 16: 12117-48. https://doi.org/10.1021/acsami.3c19308.

[136] Yildirimer L, Thanh NTK, Loizidou M, Seifalian AM Toxicology and clinical potential of nanoparticles. Nano Today 2011; 6: 585-607. https://doi.org/10.1016/j.nantod.2011.10.001.

[137] Wang P, Meyer TA, Pan V, Dutta PK, Ke Y The beauty and utility of DNA origami. Chem 2017; 2: 359-82. https://doi.org/10.1016/j.chempr.2017.02.009.

[138] Packialakshmi B, Stewart IJ, Burmeister DM, Chung KK, Zhou X Large animal models for translational research in acute kidney injury. Ren Fail 2020; 42: 1042-58. https://doi.org/10.1080/0886022X.2020.1830108.